Why the study?
Do plasma levels of imipramine correlate with adverse cardiovascular effects in prepubertal depressed children?
Do plasma levels of imipramine correlate with adverse cardiovascular effects in prepubertal depressed children?
In prepubertal children treated with imipramine, plasma levels exceeding 225 ng/ml are associated with cardiovascular adverse effects, warranting close monitoring.
Answers are grounded in this paper and cite their sources.
May support level-guided dosing to limit effects in children; extends adult data but leaves open need for prospective trials.
In 22 prepubertal depressed children, the total plasma concentration of imipramine and its major metabolite, desipramine, varied by more than sevenfold. The plasma drug concentrations correlated with slowing of intracardiac conduction, elevation of diastolic blood pressure, and increase in heart rate. These drug-induced changes were uniformly observed when the total tricyclic level exceeded 225 ng/ml. However, subjective reporting of nuisance side effects was not related to plasma drug concentration. These findings suggest that children can be safely treated when their plasma levels are below 225 ng/ml. If higher plasma levels are attained, closer monitoring is warranted.
No takes yet. Share an insight, caveat, or question.
Preskorn et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: